Affiliations: [a] Department of Electrochemistry, Institute of Chemistry, University of Bialystok, Bialystok, Poland | [b] Department of Urology, J. Sniadecki Provincial Hospital of Bialystok, Bialystok, Poland | [c] Faculty of Chemistry University of Valencia, Burjassot-Valencia, Spain
Correspondence:
[*]
Corresponding author: Ewa Gorodkiewicz, Department of Electrochemistry, Institute of Chemistry, University of Bialystok, Ciolkowskiego 1K, PL-15-245, Poland. E-mail:[email protected]
Abstract: BACKGROUND: Podoplanin (PDP) is a mucin - a type of transmembrane
protein expressed in numerous tissues during ontogeny and in adult animals,
including the brain, heart, kidney, osteoblasts and lymphoid organs. OBJECTIVE: The aim of this study was to determine podoplanin
concentration in the blood serum and urine of patients with bladder cancer.
Quantifying podoplanin concentration and its correlation with various
clinicopathological parameters may be useful for more accurate predictions
and identifying high-risk patients. METHODS: The present study included 82 patients with bladder cancer
confirmed by transurethral resection or cystectomy and 27 healthy
volunteers. The Surface Plasmon Resonance Imaging biosensor was applied for
the detection of podoplanin in the serum and urine samples. RESULTS: Significant differences in serum and urine podoplanin
concentration levels were observed between bladder cancer patients. The
statistically significant higher values of PDP were detected in serum of
patients with invasive, more aggressive, larger, multifocal tumors. CONCLUSIONS: The association between podoplanin concentration and
clinicopathological features indicates that it might be useful while making
therapeutic decisions.
